Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Botulinum toxin may help treat male pattern baldness.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

This study observed that combining botulinum toxin type A with Minoxidil significantly promoted hair growth, improved quality of life, and enhanced patient satisfaction in male androgenetic alopecia patients at 4 and 6 months, with no adverse effects compared to using Minoxidil alone.

This review reported on botulinum toxin's potential in treating dermatological conditions like hidradenitis suppurativa, rosacea, androgenetic alopecia, plaque psoriasis, and primary hyperhidrosis, highlighting initial efficacy but indicating a need for controlled trials to confirm safety and effectiveness.

This study suggests that while subcutaneous Botulinum Toxin Type A may offer short-term symptom improvement for female pattern hair loss, its effectiveness does not extend beyond three months.

This review discusses various extra facial esthetic indications of botulinum toxin, like neck rejuvenation and calf slimming, and reports no clinical results; essential tips for each indication are included.

This study found that botulinum toxin type A inhibited apoptosis in dermal papillary cells induced by dihydrotestosterone through the circ_0135062/miR-506-3p/Bax axis.

This study found that hesperidin, a bioflavonoid, mitigated the negative effects of finasteride on sperm health and testicular structure in male Wistar rats by reducing oxidative stress and apoptosis and supporting testicular antioxidant capacity.

This pilot study detailed the use of Hair-to-Hair-matching technology™ in a clinical trial to assess botulinum toxin's efficacy in treating male androgenetic alopecia, providing a precise method for evaluating hair count and thickness changes over time.

This review discusses botulinum toxin A as a treatment for various types of hair loss and reports no clinical results; the authors emphasize the need for comprehensive evaluations and further research.

This study found that patients receiving immune checkpoint inhibitors who have a history of psoriasis are at a higher risk for developing gastrointestinal and endocrine toxicities within one year compared to those without psoriasis.

In this study, injecting two different concentrations of botulinum toxin A was found to be safe and effective for treating androgenetic alopecia in Egyptian men and women, with improvements in hair grade and vellus hair density observed over six months.

This study reviewed information from various sources to highlight the versatile uses of botulinum toxin beyond aesthetic treatments, noting its successful application in fields like neurology, urology, and psychiatry, while also emphasizing its off-label therapeutic potential.

This systematic review suggests that botulinum toxin may be effective for treating certain scalp conditions, but the current evidence varies widely in quality and often derives from small observational studies.

This study surveyed UK patients who experienced adverse events from Botulinum Toxin for cosmetic purposes, finding 79% reported issues like long-lasting anxiety, and highlighting low awareness of regulatory bodies and reporting structures.

In this case report, a patient with early-stage Frontal Fibrosing Alopecia showed substantial improvement in follicular density and inflammation control after three monthly sessions of Botulinum Toxin Type A administered via microinfusion.

This study found that botulinum toxin type A may reduce apoptosis in dermal papillary cells induced by dihydrotestosterone through the circ_0135062/miR-506-3p/Bax axis.

In this study, researchers reported that conventional treatments for folliculitis decalvans, which include steroids and antibiotics, are often ineffective, with many patients experiencing frequent recurrences of this scarring scalp disorder.

This article reviews the clinical applications of botulinum toxin, highlighting its effectiveness in treating various pain conditions like diabetic neuropathy and chronic migraines and noting future research should focus on enhancing safety and efficacy.

This review reports favorable outcomes for botulinum toxin injections in androgenic alopecia treatment, but findings are limited by small sample sizes and lack of control groups.

This article discusses variations in retinoid pharmacokinetics affecting their toxicity and clinical efficacy, but reports no new results; the authors emphasize considering toxicity in selecting suitable compounds.

In this study, researchers found that the methanolic seed extract of Tectona grandis, known for its use in traditional medicine, demonstrated strong analgesic properties in Swiss albino mice, being effective at doses of 200–250 mg/kg and safe up to 1000 mg/kg.

In this study, prophylactic treatment with a neutralizing monoclonal antibody against α-toxin reduced wound sizes and bacterial burden while enhancing healing in both non-diabetic and diabetic mice with S. aureus skin infections.

This review introduces pharmacophore technology and discusses its applications in toxicity prediction and limits, but reports no new clinical results.

In this study, intradermal injection of botulinum toxin type A significantly increased hair count and improved physician-assessed hair condition in men with male pattern baldness after 24 weeks, with no serious adverse events reported beyond temporary local pain and redness.

Men are increasingly getting botulinum toxin treatments, requiring higher doses and different techniques than women for a natural look.

This article reviews skin toxicities caused by radiation in metastatic cancer patients and discusses preventive measures, highlighting that current interventions lack robust supporting data.

In this study, botulinum toxin type A did not improve clinical features in patients with recalcitrant alopecia totalis or alopecia universalis over a four-month period.

This case report presents a patient with diabetes mellitus thought to be secondary to chronic arsenic exposure, highlighting the potential need to evaluate heavy metal toxicity in similar cases.

This report describes a case of sclero-atrophy localized to the frontal scalp following an injection of botulinum toxin type A, which has not been previously documented in the literature.